BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21430096)

  • 1. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
    Peterson JF; Pfaller MA; Diekema DJ; Rinaldi MG; Riebe KM; Ledeboer NA
    J Clin Microbiol; 2011 May; 49(5):1765-71. PubMed ID: 21430096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
    J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Six Antifungal Susceptibilities of 11
    Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
    Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    J Clin Microbiol; 2007 Nov; 45(11):3522-8. PubMed ID: 17913927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
    J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
    Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
    J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.
    Cretella D; Barber KE; King ST; Stover KR
    J Med Microbiol; 2016 Dec; 65(12):1445-1451. PubMed ID: 27902377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    J Clin Microbiol; 2007 Mar; 45(3):796-802. PubMed ID: 17215344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.
    Pfaller MA; Messer SA; Diekema DJ; Jones RN; Castanheira M
    J Clin Microbiol; 2014 Jan; 52(1):108-14. PubMed ID: 24153129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.
    Arendrup MC; Park S; Brown S; Pfaller M; Perlin DS
    Antimicrob Agents Chemother; 2011 May; 55(5):1891-5. PubMed ID: 21357293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
    Fleischhacker M; Radecke C; Schulz B; Ruhnke M
    Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.
    Espinel-Ingroff A; Cantón E; Pelaez T; Pemán J
    Diagn Microbiol Infect Dis; 2011 May; 70(1):54-9. PubMed ID: 21513843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
    Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
    J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins.
    Martos AI; Romero A; González MT; González A; Serrano C; Castro C; Pemán J; Cantón E; Martín-Mazuelos E
    Med Mycol; 2010 Sep; 48(6):858-61. PubMed ID: 20144131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.